Cadrenal Therapeutics Inc. (NASDAQ: CVKD)
$17.1700
+2.6800 ( +8.06% ) 143.0K
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
Market Data
Open
$17.1700
Previous close
$14.4900
Volume
143.0K
Market cap
$28.00M
Day range
$14.2000 - $17.8240
52 week range
$5.4000 - $32.5500
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q | Quarterly Reports | 58 | Nov 07, 2024 |
8-k | 8K-related | 14 | Nov 07, 2024 |
8-k | 8K-related | 17 | Nov 04, 2024 |
8-k | 8K-related | 14 | Oct 24, 2024 |
8-k | 8K-related | 48 | Sep 25, 2024 |
8-k | 8K-related | 13 | Sep 05, 2024 |
8-k | 8K-related | 14 | Aug 20, 2024 |
8-k | 8K-related | 14 | Aug 16, 2024 |
8-k | 8K-related | 14 | Aug 08, 2024 |
10-q | Quarterly Reports | 60 | Aug 07, 2024 |